Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03468218 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
A Phase 2 study of Recurrent Head and Neck Squamous Cell Carcinoma and Recurrent Hypopharyngeal Squamous Cell Carcinoma, sponsored by Emory University.
- Active
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT03468218 is a Phase 2 study of Recurrent Head and Neck Squamous Cell Carcinoma and Recurrent Hypopharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 36 participants, below the 119-participant average among 24 other Recurrent Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03468218, a Phase 2 study of Recurrent Head and Neck Squamous Cell Carcinoma and Recurrent Hypopharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the pathways needed for cell growth. Giving pembrolizumab and cabozantinib may improve the chances of tumor response in patients with head and neck squamous cell cancer.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Cabozantinib
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University Hospital Midtown - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2026-10-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03468218
The ClinicalTrials.gov registry entry for NCT03468218 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 24 other Recurrent Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (70% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Recurrent Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03468218 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03468218 about?
NCT03468218 is a clinical study titled "Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer". This phase II trial studies how well pembrolizumab and cabozantinib in treating patients with head and neck squamous cell cancer that has come back or spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of ...
What is the current status of trial NCT03468218?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2018-09-18. Estimated completion is 2026-10-29.
What conditions does trial NCT03468218 study?
This clinical trial studies the following conditions: Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Metastatic Head and Neck Carcinoma.
What interventions are being tested in trial NCT03468218?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT03468218?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03468218 being conducted?
This trial has 2 study locations across Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RECRUITING · Phase 2
-
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
RECRUITING · Phase 2
-
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
RECRUITING · Phase 2
-
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RECRUITING · Phase 2
-
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RECRUITING · Phase 2
-
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Recurrent Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Recurrent Hypopharyngeal Squamous Cell Carcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.